Amneal Operating Cycle from 2010 to 2026

AMRX Stock  USD 12.96  0.24  1.82%   
Amneal Pharmaceuticals Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle is likely to outpace its year average in 2026. During the period from 2010 to 2026, Amneal Pharmaceuticals Operating Cycle regression line of annual values had r-squared of  0.61 and arithmetic mean of  304.29. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
266.43
Current Value
313.28
Quarterly Volatility
48.43686475
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amneal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 164.4 M, Interest Expense of 312.3 M or Selling General Administrative of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.96, Dividend Yield of 0.0728 or Days Sales Outstanding of 135. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Amneal Stock
Check out the analysis of Amneal Pharmaceuticals Correlation against competitors.

Latest Amneal Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Amneal Pharmaceuticals Class over the last few years. It is Amneal Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Amneal Operating Cycle Regression Statistics

Arithmetic Mean304.29
Geometric Mean300.55
Coefficient Of Variation15.92
Mean Deviation43.49
Median313.28
Standard Deviation48.44
Sample Variance2,346
Range141
R-Value(0.78)
Mean Square Error986.49
R-Squared0.61
Significance0.0002
Slope(7.47)
Total Sum of Squares37,538

Amneal Operating Cycle History

2026 313.28
2025 266.43
2024 231.68
2023 237.18
2022 267.17
2021 257.5
2020 252.35

About Amneal Pharmaceuticals Financial Statements

Amneal Pharmaceuticals investors use historical fundamental indicators, such as Amneal Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 266.43  313.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals' price analysis, check to measure Amneal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals is operating at the current time. Most of Amneal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.